AGIOS PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for AGIOS PHARMACEUTICALS, INC. (AGIO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are AGIO insiders buying or selling?
In the last 12 months, AGIOS PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 26 sales ($4.6M) — net selling of $4.6M. Since January 2018, Trabud has recorded 181 Form 4 filings for AGIO: 6 buys ($128.1M) and 175 sells ($72.8M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Aug 6, 2026)
Total Form 4 filings
181
SEC EDGAR
Insider filers
19
Insider buys (6)
$128.1M
Insider sells (175)
$72.8M
Insider sentiment
Net buyingNet insider flow of $55.3M in net buying since January 2018, and $4.6M in net selling over the last 12 months.
Recent AGIO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Sarah Gheuens | Chief Medical Officer | Sale | 30.0K | $30.48 | $914.4K | SEC ↗ |
| Jul 2, 2026 | Sarah Gheuens | Chief Medical Officer | Sale | 4.0K | $37.56 | $150.5K | SEC ↗ |
| Apr 6, 2026 | James William Burns | Chief Legal Officer | Sale | 3.3K | $34.71 | $113.8K | SEC ↗ |
| Apr 6, 2026 | Sarah Gheuens | Chief Medical Officer | Sale | 2.9K | $34.71 | $102.0K | SEC ↗ |
| Apr 6, 2026 | Cecilia Jones | Chief Financial Officer | Sale | 3.1K | $34.71 | $109.0K | SEC ↗ |
| Apr 6, 2026 | Tsveta Milanova | Chief Commercial Officer | Sale | 3.3K | $34.71 | $113.2K | SEC ↗ |
| Apr 6, 2026 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Sale | 3.0K | $34.71 | $102.7K | SEC ↗ |
| Apr 6, 2026 | Brian Goff | Chief Executive Officer | Sale | 19.1K | $34.71 | $661.9K | SEC ↗ |
| Mar 9, 2026 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | Sale | 3.0K | $27.80 | $82.3K | SEC ↗ |
| Mar 3, 2026 | Brian Goff | Chief Executive Officer | Sale | 18.1K | $28.96 | $522.9K | SEC ↗ |
| Mar 3, 2026 | James William Burns | Chief Legal Officer | Sale | 5.2K | $28.96 | $151.1K | SEC ↗ |
| Mar 3, 2026 | Sarah Gheuens | Chief Medical Officer | Sale | 4.1K | $28.96 | $117.4K | SEC ↗ |
| Mar 3, 2026 | Cecilia Jones | Chief Financial Officer | Sale | 5.0K | $28.96 | $145.8K | SEC ↗ |
| Mar 3, 2026 | Tsveta Milanova | Chief Commercial Officer | Sale | 2.9K | $28.96 | $83.1K | SEC ↗ |
| Mar 3, 2026 | Theodore James Washburn Jr. | Principal Accounting Officer | Sale | 2.2K | $28.96 | $64.4K | SEC ↗ |
| Jan 7, 2026 | Tsveta Milanova | Chief Commercial Officer | Sale | 2.9K | $27.02 | $77.6K | SEC ↗ |
| Jan 3, 2026 | James William Burns | Chief Legal Officer | Sale | 2.9K | $27.09 | $79.4K | SEC ↗ |
| Jan 3, 2026 | Brian Goff | Chief Executive Officer | Sale | 18.7K | $27.09 | $506.7K | SEC ↗ |
| Jan 3, 2026 | Sarah Gheuens | Chief Medical Officer | Sale | 2.9K | $27.09 | $79.4K | SEC ↗ |
| Jan 3, 2026 | Tsveta Milanova | Chief Commercial Officer | Sale | 2.9K | $27.09 | $79.4K | SEC ↗ |
| Jan 3, 2026 | Cecilia Jones | Chief Financial Officer | Sale | 2.9K | $27.09 | $79.4K | SEC ↗ |
| Nov 14, 2025 | David Scadden | Director | Sale | 200 | $43.84 | $8.8K | SEC ↗ |
| Nov 13, 2025 | Sarah Gheuens | Chief Medical Officer | Sale | 2.5K | $43.78 | $107.4K | SEC ↗ |
| Nov 3, 2025 | Sarah Gheuens | Chief Medical Officer | Sale | 200 | $43.81 | $8.8K | SEC ↗ |
| Oct 29, 2025 | Sarah Gheuens | Chief Medical Officer | Sale | 3.3K | $43.92 | $145.0K | SEC ↗ |
Showing the 25 most recent of 181 Form 4 filings for AGIOS PHARMACEUTICALS, INC..
Most active AGIO insiders
- David P Schenkein21 filings
- Christopher Bowden20 filings
- Theodore James Washburn Jr.18 filings
- Sarah Gheuens17 filings
- Scott Biller15 filings
Ask anything about AGIO insider activity
Use Trabud's AI agent to query AGIOS PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me AGIO CEO purchases this year" or compare it against any other ticker.
Open the AI agentAGIO insider trading FAQ
Are AGIOS PHARMACEUTICALS, INC. insiders buying or selling?
In the last 12 months, AGIOS PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 26 sales ($4.6M) — net selling of $4.6M. Since January 2018, Trabud has recorded 181 Form 4 filings for AGIO: 6 buys ($128.1M) and 175 sells ($72.8M). Over the full record that is net buying of $55.3M.
How many insiders trade AGIO stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for AGIOS PHARMACEUTICALS, INC.. The most recent filing was accepted on Aug 6, 2026.
Where does Trabud get AGIO insider trading data?
All AGIO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.